BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 32560058)

  • 1. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor.
    Dellal H; Boulahtouf A; Alaterre E; Cuenant A; Grimaldi M; Bourguet W; Gongora C; Balaguer P; Pourquier P
    Cells; 2020 Jun; 9(6):. PubMed ID: 32560058
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-competitive androgen receptor inhibition in vitro and in vivo.
    Jones JO; Bolton EC; Huang Y; Feau C; Guy RK; Yamamoto KR; Hann B; Diamond MI
    Proc Natl Acad Sci U S A; 2009 Apr; 106(17):7233-8. PubMed ID: 19363158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer.
    Long BJ; Grigoryev DN; Nnane IP; Liu Y; Ling YZ; Brodie AM
    Cancer Res; 2000 Dec; 60(23):6630-40. PubMed ID: 11118046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational drug design for androgen receptor and glucocorticoids receptor dual antagonist.
    Wu M; Xie Y; Cui X; Huang C; Zhang R; He Y; Li X; Liu M; Cen S; Zhou J
    Eur J Med Chem; 2019 Mar; 166():232-242. PubMed ID: 30711833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.
    Moilanen AM; Riikonen R; Oksala R; Ravanti L; Aho E; Wohlfahrt G; Nykänen PS; Törmäkangas OP; Palvimo JJ; Kallio PJ
    Sci Rep; 2015 Jul; 5():12007. PubMed ID: 26137992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade.
    Rosette C; Agan FJ; Rosette N; Mazzetti A; Moro L; Gerloni M
    Mol Cancer Ther; 2020 Nov; 19(11):2256-2266. PubMed ID: 32847976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and biological characterization of a novel series of androgen receptor modulators.
    Zhou C; Wu G; Feng Y; Li Q; Su H; Mais DE; Zhu Y; Li N; Deng Y; Yang D; Wang MW
    Br J Pharmacol; 2008 May; 154(2):440-50. PubMed ID: 18414397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Implementation of a High-Throughput High-Content Screening Assay to Identify Inhibitors of Androgen Receptor Nuclear Localization in Castration-Resistant Prostate Cancer Cells.
    Johnston PA; Nguyen MM; Dar JA; Ai J; Wang Y; Masoodi KZ; Shun T; Shinde S; Camarco DP; Hua Y; Huryn DM; Wilson GM; Lazo JS; Nelson JB; Wipf P; Wang Z
    Assay Drug Dev Technol; 2016 May; 14(4):226-39. PubMed ID: 27187604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth.
    Palit SA; Vis D; Stelloo S; Lieftink C; Prekovic S; Bekers E; Hofland I; Šuštić T; Wolters L; Beijersbergen R; Bergman AM; Győrffy B; Wessels LF; Zwart W; van der Heijden MS
    Elife; 2019 Dec; 8():. PubMed ID: 31855178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computationally guided discovery of novel non-steroidal AR-GR dual antagonists demonstrating potency against antiandrogen resistance.
    Chai X; Hu XP; Wang XY; Wang HT; Pang JP; Zhou WF; Liao JN; Shan LH; Xu XH; Xu L; Xia HG; Hou TJ; Li D
    Acta Pharmacol Sin; 2023 Jul; 44(7):1500-1518. PubMed ID: 36639570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of an anabolic selective androgen receptor modulator that actively induces death of androgen-independent prostate cancer cells.
    Schmidt A; Meissner RS; Gentile MA; Chisamore MJ; Opas EE; Scafonas A; Cusick TE; Gambone C; Pennypacker B; Hodor P; Perkins JJ; Bai C; Ferraro D; Bettoun DJ; Wilkinson HA; Alves SE; Flores O; Ray WJ
    J Steroid Biochem Mol Biol; 2014 Sep; 143():29-39. PubMed ID: 24565564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and biological evaluation of novel androgen receptor antagonist for castration-resistant prostate cancer.
    Yu J; Zhang L; Yan G; Zhou P; Cao C; Zhou F; Li X; Chen Y
    Eur J Med Chem; 2019 Jun; 171():265-281. PubMed ID: 30925341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darolutamide as a Second-Generation Androgen Receptor Inhibitor in the Treatment of Prostate Cancer.
    Abbasi A; Movahedpour A; Amiri A; Najaf MS; Mostafavi-Pour Z
    Curr Mol Med; 2021; 21(4):332-346. PubMed ID: 32881669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate Cancer.
    He Y; Hwang DJ; Ponnusamy S; Thiyagarajan T; Mohler ML; Narayanan R; Miller DD
    J Med Chem; 2020 Nov; 63(21):12642-12665. PubMed ID: 33095584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drivers of AR indifferent anti-androgen resistance in prostate cancer cells.
    Handle F; Prekovic S; Helsen C; Van den Broeck T; Smeets E; Moris L; Eerlings R; Kharraz SE; Urbanucci A; Mills IG; Joniau S; Attard G; Claessens F
    Sci Rep; 2019 Sep; 9(1):13786. PubMed ID: 31551480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of androgen refractory prostate cancer cells to anti-androgens through re-expression of epigenetically repressed androgen receptor - Synergistic action of quercetin and curcumin.
    Sharma V; Kumar L; Mohanty SK; Maikhuri JP; Rajender S; Gupta G
    Mol Cell Endocrinol; 2016 Aug; 431():12-23. PubMed ID: 27132804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second generation androgen receptor antagonists and challenges in prostate cancer treatment.
    Chen Y; Zhou Q; Hankey W; Fang X; Yuan F
    Cell Death Dis; 2022 Jul; 13(7):632. PubMed ID: 35864113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A; Czwornog J; Gera L; Joshi S; Chatterton RT; Budunova I
    Cancer Res; 2008 Jun; 68(12):4763-73. PubMed ID: 18559523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.